Atrial Fibrillation
Conditions
Keywords
Atrial fibrillation, Catheter ablation, Arrhythmia, Biomarkers
Brief summary
Atrial fibrillation ablation is the most common intervention performed worldwide. Up to 20 to 45% of patients show recurrence of AF within 12 month after catheter ablation, however its determinant are incompletely understood. The aim of the PROSPECT-AF study is to assess the predictors of AF recurrence within the 3 years following ablation using clinical variables and innovative biomarkers in a prospective cohort of 750 patients undergoing atrial fibrillation catheter ablation. The secondary aims are to assess the incidence of major adverse cardiovascular outcomes (MACE) and the incidence of major bleeding within the 3 years Wolfing catheter ablation.
Interventions
The ablation is performed under local anesthesia or general anesthesia. A transseptal puncture will be performed to access the left atrium. Pulmonary vein isolation will be performed as a first step. Additional lesions will be made at the discretion of the operators. Patients will receive anticoagulation for at least 3 months after the ablation. Treatment thereafter will be extended at the discretion of the treating physician.
Sponsors
University Hospital, Lille
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient undergoing atrial fibrillation catheter ablation * Able to give their consent
Exclusion criteria
* Childs * Patient under guardianship * Patients unable to give their consent * Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of atrial fibrillation recurrence. | At 3 years |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of major adverse cardiovascular events (MACE) including hospitalization for acute heart failure, cardiovascular death, stroke, myocardial infarction | At 3 years |
| Incidence of major bleeding (defined by BARC≥3 bleeding) | At 3 years |
Countries
France
Contacts
Primary ContactSandro Ninni, MD
Outcome results
None listed